SCHEMBL8225933

SCHEMBL8225933

O=C1c2cc(O)c(O)cc2CC1C(O)C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 7/20 0.51
▸ BCHE P06276 3/20 0.47
▸ FAAH O00519 1/20 0.46
▸ ABCC4 O15439 1/20 0.46
▸ CACNA1F O60840 1/20 0.46
▸ PDE5A O76074 1/20 0.46
▸ ABCB11 O95342 1/20 0.46
▸ APP P05067 1/20 0.46
▸ CHRM2 P08172 1/20 0.46
▸ ABCB1 P08183 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CHRM5 P08912 1/20 0.46
▸ ADRA2A P08913 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ ADRA2C P18825 1/20 0.46
▸ DRD4 P21917 1/20 0.46
▸ SLC6A2 P23975 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ AGTR1 P30556 1/20 0.46
▸ ADRA1A P35348 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28409650 0.85 ACHE (0.71) ACHEBCHEFAAHABCC4CACNA1F
SCHEMBL28409647 0.85 ACHE (0.71) ACHEBCHEFAAHABCC4CACNA1F
SCHEMBL28412550 0.85 ACHE (0.71) ACHEBCHEFAAHABCC4CACNA1F
SCHEMBL4306013 0.85 ACHE (0.71) ACHEBCHEFAAHABCC4CACNA1F
SCHEMBL28412286 0.85 ACHE (0.71) ACHEBCHEFAAHABCC4CACNA1F
SCHEMBL13858798 0.85 ACHE (0.57) ACHEBCHEFAAHABCC4CACNA1F
SCHEMBL28412284 0.85 ACHE (0.71) ACHEBCHEFAAHABCC4CACNA1F
SCHEMBL28409648 0.85 ACHE (0.71) ACHEBCHEFAAHABCC4CACNA1F
SCHEMBL28551429 0.85 ACHE (0.71) ACHEBCHEFAAHABCC4CACNA1F
SCHEMBL28412287 0.85 ACHE (0.71) ACHEBCHEFAAHABCC4CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113793-A1 Process for the Preparation of Highly Pure Donepezil IND-SWIFT LABORATORIES LIMITED (IN) 2010-05-06 — — US disclosed
EP-1992616-A1 Process for the preparation of donepezil and intermediate compounds thereof as well as hydrates of donepezil Pliva Hrvastka D.O.O. (HR) 2008-11-19 — — EP disclosed
WO-2007108011-A2 PROCESS FOR THE PREPARATION OF HIGHLY PURE DONEPEZIL IND-SWIFT LABORATORIES LIMITED (IN) 2007-09-27 — — WO disclosed
WO-2007015052-A1 PROCESS FOR THE PREPARATION OF DONEPEZIL AND INTERMEDIATE COMPOUNDS THEREOF AS WELL AS HYDRATES OF DONEPEZIL PLIVA ISTRAZIVANJE I RAZVOJ D.O.O. (HR) 2007-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113793-A1 Process for the Preparation of Highly Pure Donepezil PSEN1, ACHE, PSEN2 ACHE 2/4885BCHE 5/4885FAAH 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback